1. Home
  2. LIXT vs NOTE Comparison

LIXT vs NOTE Comparison

Compare LIXT & NOTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lixte Biotechnology Holdings Inc.

LIXT

Lixte Biotechnology Holdings Inc.

HOLD

Current Price

$3.99

Market Cap

25.4M

Sector

Health Care

ML Signal

HOLD

Logo FiscalNote Holdings Inc.

NOTE

FiscalNote Holdings Inc.

HOLD

Current Price

$1.69

Market Cap

27.5M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
LIXT
NOTE
Founded
2005
2013
Country
United States
United States
Employees
N/A
439
Industry
Biotechnology: Pharmaceutical Preparations
EDP Services
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
25.4M
27.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
LIXT
NOTE
Price
$3.99
$1.69
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$29.25
AVG Volume (30 Days)
90.8K
235.5K
Earning Date
11-12-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$102,673,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$0.55
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.64
$1.75
52 Week High
$6.26
$24.36

Technical Indicators

Market Signals
Indicator
LIXT
NOTE
Relative Strength Index (RSI) 42.98 24.45
Support Level $4.01 $1.88
Resistance Level $4.40 $1.94
Average True Range (ATR) 0.31 0.18
MACD -0.01 0.03
Stochastic Oscillator 22.34 7.50

Price Performance

Historical Comparison
LIXT
NOTE

About LIXT Lixte Biotechnology Holdings Inc.

Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.

About NOTE FiscalNote Holdings Inc.

FiscalNote Holdings Inc is a provider of world-wide policy and market intelligence solutions. Leveraging AI and analytics, it delivers actionable legal and policy insights for businesses, government institutions, and nonprofits. Its suite of products includes FiscalNote Core, CQ Federal, and EU Issue Tracker, facilitating effective policy management and risk mitigation. With its analysis from FrontierView, Oxford Analytica, and Dragonfly Eye, it offers geopolitical and market intelligence services. Operating as one segment, it generates revenue by integrating policy intelligence into daily operations. Geographically the company generates the majority of its revenue from North America, Europe, Australia, and Asia, with the majority generated from North America.

Share on Social Networks: